Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEEHIVE: Novavax vs. Pfizer COVID-19 2023-2024 Boosters
NCT06065176Phase 4Completed
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19). Started Nov 2023; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06065176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065176.